Slide Shows & Poster Presentations

Date Description Author
2017-01-09 January 2017 Corporate Presentation Oncolytics Biotech Inc.
2016-12-06 Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Dr. Kevin Kelly
2015-12-08 REOLYSIN® Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients Dr. D.W. Sborov
2015-09-25 Combination Carfilzomib and the Viral Oncolytic Agent REOLYSIN® in Patients with Relapsed Multiple Myeloma: A Pilot Study Investigating Viral Proliferation Dr. D.W. Sborov
2015-08-27 Oncolytic Reovirus in Combination with Paclitaxel/Carboplatin in NSCLC Patients with Ras Activated Malignancies, Long Term Results Dr. Miguel A. Villalona-Calero
2015-07-06 Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma Mahalingam et al
2015-06-15 9th International Conference on Oncolytic Virus Therapeutics Collaborator Abstracts and Posters Various
2015-04-20 AACR 2015 Annual Meeting Collaborator Poster Presentations Various
2015-04-15 REOLYSIN® and Immune Therapy: Rationale for Combination Therapy Dr. Matt Coffey
2015-03-26 REOLYSIN® and Immune Checkpoint Inhibitors: Rationale for Combination Therapy Dr. Giovanni Selvaggi
2015-03-05 Synergistic Combination of Oncolytic Reovirus Type 3 (Dearing) and Radiotherapy in Melanoma is Mediated Through Enhanced Viral Replication and Mitochondrial Apoptotic Signalling. Harrington, et al.